| Abstrakt: |
Research conducted at the State University of New York (SUNY) Buffalo suggests that increasing cyclic GMP may improve proteostasis and reduce neuropathy in mouse models of Charcot Marie Tooth (CMT) 1A and 1B peripheral neuropathies. The study found that pharmacologically increasing cGMP through specific agents activated proteasomes, reduced polyubiquitinated proteins, and improved myelin thickness and nerve conduction in affected peripheral nerves. This research, supported by the NIH National Institute of Neurological Disorders & Stroke (NINDS), indicates that agents that raise cGMP could be promising treatments for CMT1 neuropathies and potentially other proteotoxic and neurodegenerative diseases. [Extracted from the article] |
